T1	Participants 860 868	patients
T2	Participants 1303 1314	80 patients
T3	Participants 1337 1357	31 preferred placebo
T4	Participants 1137 1189	79 received fluorouracil/epirubicin/cyclophosphamide
T5	Participants 1194 1235	15 received doxorubicin/cyclophosphamide.
T6	Participants 1387 1439	37 (46 %, 95 % CI: 35-58 %) preferred dexamethasone;
T7	Participants 1440 1461	12 had no preference.
